Video
Study measures patient rankings of third-line OAB treatments
Author(s):
“We wanted to help provide an understanding of what factors guide patient choice of third line therapy for overactive bladder,” says Anjali Kapur, MD.
Video Player is loading.
In this video, Anjali Kapur, MD, discusses the background and notable findings of the recent Neurourology and Urodynamics paper, “An analysis of factors that influence patient preference of third-line therapy for overactive bladder.” Kapur is a urology resident at Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Andrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation system
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Post-RP incontinence: Low procedure rates examined
Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
Data link incontinence severity to post-radical prostatectomy care
OnabotA for OAB: Enhancing comfort and ensuring adherence
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Administering onabotA: Improving patient comfort and easing anxiety
Related Content
